Webinar On-Demand
About the Webinar
Is your clinical trial site ready to participate in the future of medicine? Cutting-edge therapies like mRNA vaccines, viral vectors, and cellular treatments require robust biosafety oversight. But navigating these complexities shouldn’t limit your research potential. This webinar is designed for all clinical trial sites and site networks, regardless of current IBC registration status.
Open Doors to New Trials: Discover how a centralized IBC can unlock access to a wider range of clinical research opportunities, including those involving:
- Emerging Therapies: Be at the forefront of groundbreaking treatments by ensuring your site is qualified to participate.
- Specialized Protocols: Gain the expertise needed to handle complex research protocols with confidence.
- Sponsor Partnerships: Attract new sponsors seeking qualified sites for cutting-edge research.
Already IBC Registered? Registering with multiple IBCs can still be a valuable asset, offering:
- Enhanced Expertise: Gain access to a wider pool of biosafety specialists for complex protocols.
- Streamlined Review Process: Expedite study initiation with efficient centralized reviews.
- Standardized Practices: Ensure consistent and compliant biosafety across all your research.
- Reduced Administrative Burden: Free up your staff to focus on core research activities.
Not Yet Registered? Learn how a centralized IBC can:
- Simplify Compliance: Ensure your site meets all biosafety requirements with expert guidance.
- Enhance Research Capabilities: Gain access to the resources needed to handle cutting-edge therapies.
- Optimize Workflows: Streamline your research process with efficient review timelines.
Join WCG’s webinar and discover how a centralized IBC can revolutionize your research environment. Regardless of your current registration status, this informative session will equip you with the tools to expand your research horizons and navigate the future of biosafety with confidence.
Meet the Speakers
Daniel Kavanagh
Senior Scientific Advisor, Gene Therapy, Vaccines & Biologics
Luke Goodpaster
Director, WCG Site Network